Financial Performance - The Group reported a revenue of SGD 3,662,000 for Q1 2023, representing a 40% increase from SGD 2,614,000 in Q1 2022[12] - Gross profit for Q1 2023 was SGD 943,000, up 43.5% from SGD 657,000 in Q1 2022[12] - Profit before taxation increased to SGD 50,000 in Q1 2023, compared to SGD 18,000 in Q1 2022, marking a 177.8% growth[12] - The earnings per share for Q1 2023 was SGD 0.01, compared to less than SGD 0.01 in Q1 2022[12] - The total comprehensive income for the period was SGD 50,000, significantly higher than SGD 18,000 in the same period last year[12] - Revenue for Q1 2023 was $3.7 million, an increase of 40.1% compared to Q1 2022, primarily due to higher orders of tissue products from corporate customers[42] - Profit for Q1 2023 was $50,000, representing a 177.8% increase from Q1 2022, mainly driven by the increase in revenue[42] - Sales of tissue products amounted to $3.26 million in Q1 2023, up from $2.28 million in Q1 2022, reflecting a growth of 43.2%[28] - Hygiene-related products generated revenue of $231,000 in Q1 2023, compared to $209,000 in Q1 2022, marking an increase of 10.6%[28] - The profit attributable to shareholders for the Relevant Period was $50,000, representing an increase of 177.8% compared to $18,000 in the Previous Period[68][72] - Revenue for the Relevant Period was $3.7 million, an increase of $1.1 million or 40.1% from the Previous Period revenue of $2.6 million[60][62] Expenses and Costs - Administrative expenses rose to SGD 452,000 in Q1 2023 from SGD 323,000 in Q1 2022, reflecting a 40% increase[12] - The cost of inventories recognized in cost of sales was $2.52 million in Q1 2023, up from $1.82 million in Q1 2022, indicating a rise of 38.7%[30] - Cost of sales increased from $2.0 million to $2.7 million, representing an increase of 38.9%[61][63] - Selling and distribution expenses rose from $361,000 to $443,000, an increase of 22.7%[65][69] - Administrative expenses increased from $323,000 to $452,000, representing a rise of 39.9% due to global inflation[66][70] Corporate Governance and Compliance - The Group's financial results are unaudited, highlighting the need for careful consideration by investors[12] - The report will be available on the Stock Exchange's website for at least 7 days, ensuring transparency and accessibility of information[6] - The company has adopted the Corporate Governance Code to ensure proper regulation of business activities and decision-making processes[101] - The Audit Committee consists of three independent non-executive directors, ensuring appropriate financial oversight[103] - All Directors confirmed compliance with the Required Standard of Dealings during the Relevant Period[92] - There were no competing interests reported by Directors or Controlling Shareholders during the Relevant Period[94] - All directors confirmed compliance with the trading standards during the relevant period[98] Market and Operational Strategy - The company is primarily engaged in supplying tissue products to corporate customers in Singapore, indicating a focus on market expansion in this sector[18] - The company continues to supply tissue products to corporate customers in Singapore, with no significant impact on operations due to COVID-19 restrictions during the relevant period[40][41] - The company has implemented strategies to mitigate risks associated with COVID-19, including appointing external logistics providers and stocking up on inventory[41] - The overall strategy during the COVID-19 pandemic has been to avoid self-inflicted interruptions to operations, with all employees vaccinated[51][53] - The company is optimistic about achieving sustainable growth and is committed to delivering greater returns to shareholders[56][58] Shareholder Information - Mr. Chua Liang Sie and Mr. Chua Liang Chui hold a combined total of 576,000,000 shares in YJH Group Limited, representing 72% of the total issued shares[76] - Mr. Chua Liang Sie owns approximately 82.76% of YJH Group Limited, while Mr. Chua Liang Chui owns 17.24%[80] - No share options have been granted under the Share Option Scheme since its adoption, and there are no outstanding options as of the end of the Relevant Period[89] - The Company did not redeem any of its listed securities during the Relevant Period[91] - The company has not repurchased any of its listed securities during the relevant period[97] - The company will continue to review the separation of the roles of Chairman and Chief Executive Officer as appropriate[102] Future Outlook - Forward-looking statements in the report involve known and unknown risks that could cause actual results to differ materially[107] - The company has projected a revenue growth of YY% for the full fiscal year 2023, driven by new product launches and market expansion strategies[122] - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the industry[124] - A new marketing strategy has been implemented, aiming to increase brand awareness and customer engagement by FF%[124] - The company has successfully restructured its operations, resulting in improved efficiency and cost savings of approximately S$GG million annually[124]
日光控股(08451) - 2023 Q1 - 季度财报